Newsfeeds - Spark Newswire

2 minute read

News

MaxCyte Signed Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

Today, 8:52 AM

MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat

MXCT

1 minute read

MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders

By Vandana Singh

Today, 8:52 AM

MaxCyte Inc (NASDAQ: MXCT) has signed a

CRSP

1 minute read

MaxCyte Signs Strategic Platform License With Vertex Pharmaceuticals To Advance CRISPR/Cas9-Based Gene-Editing Program

By Bill Haddad

Today, 8:52 AM

Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for

MXCT

1 minute read

BTIG Maintains Buy on MaxCyte, Raises Price Target to $11

By Benzinga Newsdesk

Today, 8:52 AM

BTIG analyst Mark Massaro maintains MaxCyte (NASDAQ:MXCT) with a Buy and raises the price target from $10 to $11.

MXCT

11 minute read

Earnings Scheduled For August 10, 2022

By Benzinga Insights

Today, 8:52 AM

Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.

AADI

1 minute read

Earnings

A Preview Of MaxCyte’s Earnings

By Benzinga Insights

Today, 8:52 AM

MaxCyte (NASDAQ:MXCT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that MaxCyte will report an earnings per share (EPS) of $-0.08.

MXCT

24 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 8:52 AM

On Friday, 422 stocks made new 52-week lows.

AAT

2 minute read

Earnings

Looking Into MaxCyte’s Return On Capital Employed

By Benzinga Insights

Today, 8:52 AM

According to Benzinga Pro data, during Q1, MaxCyte (NASDAQ:MXCT) posted sales of $11.59 million. Earnings were up 16.56%, but MaxCyte still reported an overall loss of $4.07 million.

MXCT

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 8:52 AM

On Wednesday, 807 companies reached new 52-week lows.

AADI

16 minute read

Earnings Scheduled For May 9, 2022

By Benzinga Insights

Today, 8:52 AM

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

ACM